EGFR and nonpapillary renal cell carcinoma: Obvious tumor heterogeneity, distinct PD-L1 expression, and TIME were observed between the two subtypes, which will contribute to the risk stratification and precision therapy for patients with ccRCC, and we also found that the interaction between ferroptosis and the ERBB signaling pathway might be implicated in regulating the TIME of ccRCC.